Loading...
Market
Largest market share for diabetes treatment in Brazil by end of 2025?
2
Resolution / Starting Odds
Novo Nordisk • 25%
EMS • 25%
Sanofi • 25%
Other • 25%
Market research reports and sales data published by industry analysts
Story
Anvisa Approves EMS Production of Liraglutide Medications Lirux and Olire, First Competitor to Ozempic, for Sale in 2025
Dec 24, 2024, 02:11 PM
The Brazilian Health Regulatory Agency (Anvisa) has approved the production of two liraglutide-based medications by the pharmaceutical company EMS. The drugs, named Lirux and Olire, are intended for the treatment of type 2 diabetes and obesity, respectively. This marks the introduction of the first national competitor to Ozempic, a medication widely used for similar purposes. The approval was officially published in the Diário Oficial on December 23, 2024, and the medications are expected to be available for commercial sale in 2025. In a separate development, Anvisa has prohibited a supplement that falsely claimed to cure diabetes, which had been linked to misleading information about the disease.
View original story
Similar markets
Remain the same • 25%
Other • 25%
Increase • 25%
Decrease • 25%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Wegovy • 25%
Ozempic • 25%
Mounjaro • 25%
Other • 25%
Novo Nordisk 40-60% • 25%
Novo Nordisk > 60% • 25%
Eli Lilly 40-60% • 25%
Eli Lilly > 60% • 25%
Less than 30% • 25%
More than 50% • 25%
40% to 50% • 25%
30% to 40% • 25%
Yes • 50%
No • 50%
Decrease • 25%
No change • 25%
Slightly increase • 25%
Significantly increase • 25%
50% to 75% • 25%
25% to 50% • 25%
Less than 25% • 25%
More than 75% • 25%
Top 20 • 25%
Top 5 • 25%
Top 10 • 25%
Below Top 20 • 25%
No significant change • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Outside top 5 • 25%
Top 5 in the sector • 25%
Leader in the sector • 25%
Top 3 in the sector • 25%